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Reply to the Letters from Murray et al. and Vianna-
Morgante and Costa
To the Editor:
It was with great interest that we read the letter to
the editor by Murray et al. (2000 [in this issue]), and
we thank the authors for their comments. We agree
that it would be very interesting to know whether
other investigators observe a parent-of-origin effect in
the development of premature ovarian failure (POF)
in premutation carriers, as we have stated in our paper
(Hundscheid et al. 2000). Murray et al. reevaluated
their results and did not observe such an effect. There
may be several explanations for this. The etiology of
POF is extensive and comprises genetic, nongenetic,
and multifactorial components. Therefore, it is not
unlikely that there are differences between families
with fragile X who are from the United Kingdom and
those that are from The Netherlands. More impor-
tantly, differences in study design (especially for mul-
ticenter studies) will inevitably lead to other results
and, subsequently, will lead to other conclusions.
We were very surprised by the mean age at menopause
mentioned by Murray et al. In the premutation group,
the mean age at menopause was 47.87 years, compared
with 52.96 years in the full-mutation and normal groups
combined. In our ongoing study, the mean age at men-
opause in premutation carriers who had experienced
spontaneous menopause was 42.0 years (unpublished
data); this finding is in line with observations made else-
where (see Partington et al. 1996). When we performed
Kaplan-Meier survival analysis on the entire group of
premutation carriers, the mean age at menopause was
45 years. This finding strongly suggests that the study
population of Murray et al. differs from ours. To verify
our observation of imprinting, the mean age at meno-
pause has to be comparable. A significantly lower mean
age may point to a different population, a difference in
the occurrence of POF, or the number of premutation
carriers that are postmenopausal. If this is the case, then
it is obvious that one cannot compare the two studies.
Murray et al. have shown that, of 116 women who
were premutation carriers, 51 had a paternally inherited
fragile X premutation (PIP), 40 had a maternally inher-
ited fragile X mutation (MIP), and 25 had an unknown
parental origin of premutation. Of the 91 women in
whom the parental origin of the premutation could be
established, only 30 (33%) were of age 40 years. We
have described 148 premutation carriers in whom the
parental origin of the premutation could be determined:
106 women with a PIP and 42 women with a MIP. Of
the 106 women with a PIP, 82 were of age 40 years,
and, of the 42 women with a MIP, 27 were of age 40
years. Thus, in our study, 109 (74%) of 148 women
were of age 40 years and did not experience non-
spontaneous cessation of menstruation at age !40 years.
Therefore, we have to conclude that the proportion of
women in whom the occurrence of POF can be estab-
lished (only in women of age 40 years) is significantly
higher in our study, compared with the study byMurray
et al. This may be the result of other methodology, which
may also account for the low numbers of observed
women with a PIP. This makes it rather impossible to
compare the data.
University Hospital Nijmegen has been extensively
studying families with fragile X, tracing possible car-
riers in several generations. We have estimated that
the overall frequency of carriers of a PIP is approxi-
mately three times higher than that of carriers of a
MIP. On the basis of this finding, we cannot reason
why Murray et al. identified 51 women with a PIP
and 40 women with a MIP. This other PIP:MIP ratio
may be an indication that Murray et al. did not study
the families to the same extent that we did. Murray
et al. might possibly have included a large proportion
of first-degree relatives in the younger generation.
This will result in a different population with other
observations that cannot be compared.
Since the etiology of POF is extensive, we think that
it is of paramount importance to check medical histories
with attending physicians, to avoid misclassification.
Checking the dates with attending physicians may also
help to avoid a patient’s recall bias; postmenopausal
women have a tendency to round off their age at men-
opause to the nearest age that ends in the numeral 0 or
5 (Partington et al. 1996).
We have to conclude that, in a comparison of our
study with that of Murray et al., there are differences
in methodology, mean age at menopause, and number
of women in whom the occurrence of POF can be es-
tablished. This probably reflects a different population,
and we therefore doubt whether the results can be com-
pared. We agree that it is remarkable that Murray et al.
did not observe the same parent-of-origin effect that we
observed. Therefore, we would like to invite groups with
a population and methodology comparable to ours to
verify our observation and to report their findings.
The reply we addressed to the letter to the editor sub-
mitted by Murray et al. applies to that submitted by
Vianna-Morgante and Costa (2000 [in this issue]) as
well. The population in the study by Vianna-Morgante
and Costa is very young, compared with that in our
study. The population’s median age at examination, for
women with a MIP ( ), was 36.83 years, and, forn = 27
women with a PIP ( ), the median age was 38.875n = 32
years. In our study, for women with a MIP ( ), then = 42
median age at examination was 51.5 years, and, for
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those with a PIP ( ), the median age was 50.0n = 106
years. Besides the fact that the PIP:MIP ratio (32:27)
mentioned in the letter by Vianna-Morgante and Costa
differs substantially from ours (106:42), we have a much
older population. Moreover, this major difference in the
study population is again emphasized by the fact that,
in the study by Vianna-Morgante and Costa, 15 women
with a PIP and 10 women with a MIP were of age 40
years. This number is very low compared with our find-
ing (82 women with a PIP and 27 with a MIP, all of age
40 years). Again, this points out that their population
is different than ours—a fact that obviously will lead to
other results.
Vianna-Morgante and Costa have compared the oc-
currence of POF in women with a PIP with that in
women with a MIP, and they have concluded that there
is no difference between the two groups. However, their
analysis incorporated data on women of age !40 years.
Since POF is defined as a condition occurring at age !40
years, it can only be established reliably in women of
age 40 years. Not only will establishment of the oc-
currence of POF in women who have not reached the
age of 40 years result in a higher risk for misclassification
toward POF, but, in the majority of cases, occurrence
of the condition cannot even be established. Hence, we
think it is remarkable that the authors also included
women of age !40 years in their study. Moreover, the
mean age of the participants in their study is below the
cutoff level for age. Therefore, the numbers they pre-
sented probably will not represent the final (as estab-
lished only in women of age 40 years) occurrence and
distribution of POF. In the letter, 14 (24%) of 59 women
with either a PIP or a MIP had POF—a finding that is
an underestimation of the real (probably even higher)
occurrence of POF. Since 16% of women with premu-
tations experience POF (Allingham-Hawkins et al.
1999), we wonder whether the population in the study
of Vianna-Morgante and Costa (in which 24% of the
women had POF) is randomly selected. In our ongoing
study of families with fragile X, we have randomly se-
lected women on the basis of mutation and not on the
basis of indication of POF.
Last but not least, for both groups of women, the
authors calculated the median and mean age at meno-
pause (see also table 1 in the study by Vianna-Morgante
and Costa). The numbers on which these calculations
are based are very small (13 women with a PIP and 9
women with a MIP), and, to us, it is not clear which
data the authors have included in their calculations. If
the authors included women with POF when they cal-
culated mean age at menopause, then their calculation
would not result in a reliable mean age at menopause.
For instance, for women with a PIP, the mean age at
menopause was based on 13 women who have experi-
enced spontaneous menopause. If the authors also used
the data on the women with POF, then it can be inferred
that only four women who did not experience POF were
used in this calculation. The mean age at menopause
that is presented is not representative of that in all
women with a PIP. Thus, on the basis of these numbers,
we do not subscribe to the authors’ conclusion that there
is no difference between the two groups, as far as age
at menopause is concerned.
In conclusion, neither Murray et al. nor Vianna-Mor-
gante and Costa can confirm our observation of a par-
ent-of-origin effect. Both groups have younger popula-
tions, other PIP:MIP ratios, and a sample size that is
much smaller than ours. We therefore do not follow
Vianna-Morgante and Costa’s suggestion that a “pos-
sible genomic imprinting effect may be peculiar to the
Dutch population,” since no sufficient convincing evi-
dence of this is provided. Nevertheless, if the parent-of-
origin effect that we have observed cannot be demon-
strated by other authors, then we have to conclude either
that the parent-of-origin effect is unique to the Dutch
population with fragile X or that we all are overlooking
some other factors (bias or nonbias).Whatever is causing
this discrepancy, it will be of major importance with
regard to future research (and which methodology is to
be used) in this particular field. However, we think that
it is too premature to draw final conclusions with regard
to the parent-of-origin effect. Our population and meth-
odology differ too much from those described by Mur-
ray et al. and by Vianna-Morgante and Costa. Further
research is warranted to verify our observation.
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Inflated False-Positive Rates in Hardy-Weinberg and
Linkage-Equilibrium Tests Are Due to Sampling on
the Basis of Rare Familial Phenotypes in Finite
Populations
To the Editor:
If it is assumed that genotypes of some locus (GD) are
in Hardy-Weinberg equilibrium (HWE) in a population
and that these genotypes are correlated with some phe-
notype (Ph), then, among “cases” in the tail of the dis-
tribution of Ph (equivalently, affected with rare dis-
ease), the GD will show Hardy-Weinberg disequilibrium
(HWD) (Nielsen et al. 1999; Deng et al. 2000; Go¨ring
and Terwilliger 2000). However, this does not imply that
“generally, in individuals at either end of the quantita-
tive-trait distribution, HWD exists if and only if there
exists a whole-population LD [i.e., “linkage disequilib-
rium”]” (Deng et al. 2000, p. 1030). The “only if” part
of this sentence is not correct. Even Deng et al. ( 2000,
p. 1044) point out that “an absence of HWD does not
imply that a marker locus and a QTL are not in LD”
and that, for completely random marker loci, there will
be inflated false-positive rates in tests for HWD (and LD
as well), because “cases” of familial disease tend to be
more related than “controls,” for the following reasons.
Assume that Ph is correlated in families, without spec-
ifying whether this is due to genetic or shared environ-
mental factors. Let the prevalence, f = P(individual B is
a case), and the familial relative risk l = P(individual B
is a caseFrelative A is a case)/f (Weiss et al. 1982; Risch
1990). Then, P(A and B are affectedFA and B are rel-
atives) = lf2, and P(A and B are affected ) = f2 if they
are randomly ascertained. This implies that P(A and B
are relativesFA and B are affected) = lf2P( A and B are
relatives)/f 2 = lP(A and B are relatives). If , thenl 1 1
ascertainment of “cases” ascertains relativeswith greater
probability than does random ascertainment of “con-
trols,” leading to increased false-positive evidence of
HWD and LD throughout the genome. This effect will
be largest when l is large, f is small, and the population
is small and/or structured (such that P[A and B are rel-
atives] is nontrivial). In a sense, this is related to the
problem of population stratification when the phenotype
being studied correlates with a familial stratum, regard-
less of whether the trait is “genetic” (see Chase 1977).
If the “case” phenotype is a good predictor of GD (a
prerequisite for mapping to be powerful), then a large
portion of the “case” sample will share some risk allele
IBD from some common ancestor. The coalescent path
connecting these chromosomes historically defines the
most distant possible relationship among the “cases”
carrying this allele, defining an upper bound on how
“unrelated” they could possibly be. Again, this implies
that ascertainment of affected individuals increases the
probability of ascertainment of relatives. And the less
frequent the shared risk allele is, the more closely related
the “case” individuals will be (see Terwilliger, in press),
leading to potential deviations from HWE and LE in
unrelated parts of the genome as well.
The more closely related two people are, the larger
the proportion of their genomes that they will share, as
measured by their kinship coefficient (also see Terwilli-
ger et al. 1997). If cases are “more related” than con-
trols, then they will, with higher probability than will
be seen in controls, share alleles IBD at random places
in the genome, leading to increased false-positive rates
in HWD and LD tests. This anticonservative behavior
may be minor in studies of a single marker locus, but,
when one considers the effects of testing hundreds of
thousands of markers jointly in a genome scan, often
making inferences based on the most significant values
of the test statistic over the genome, the inflation of the
type I error can have significant import. Furthermore,
because the effect of small deviations, from HWE and/
or LE, that are induced by such sampling is to shift the
distribution slightly upward, the anticonservative bias
will increase as we look farther out into the tail of the
pointwise distribution (data not shown—but similar in
shape to what appears in fig. 4 of Go¨ring and Terwilliger
2000), leading to potentially gross inflation of genome-
wide false-positive rates. To test for such problems, one
can do a Monte Carlo randomization, as was done, in
a case-control study of a small genetically homogeneous
population isolate, by Hovatta et al. (1999), who kept
the genotypes (for the whole genome scan) of all indi-
viduals constant and randomized their phenotypes
(“case” and “control”). The simulation showed that
their sample had approximately twice as many positives
as would be expected from the randomization test, con-
sistent with what is expected for reasons described in
this note. When the fundamental assumption that
“cases” and “controls” are independent and identically
distributed with respect to random marker-locus geno-
type frequencies throughout the genome appears to have
been rejected, it is essential to maintain skepticism in the
interpretation of the results of such an analysis.
Unfortunately, the conditions in which “cases” are
most likely to be relatives (e.g., small populations, rare
